A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women (ASPIRE)
Sponsors: Division of AIDS, US National Institute of Allergy and Infectious Diseases (NIAID)
US National Institutes of Health (NIH)
Protocol Summary: ASPIRE – A Study to Prevent Infection with a Ring for Extended Use, also known as MTN-020, is a Phase III study that seeks to determine whether a woman’s use of a vaginal ring containing the antiretroviral (ARV) drug dapivirine is a safe and effective method for protecting against HIV infection. The study will enroll approximately 3,476 women at several sites in Africa beginning mid 2012 and take approximately two years to conduct, with results anticipated late 2014 or early 2015.
Years: 2012 – 2015
Investigator: Z.M. Chirenje, MD, FRCOG
Locations: Spilhaus, Seke South, and Zengeza CRSs
Baeten JM, Planee-Phillips T, Brown ER, et. al. (2016) Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016 Dec 1;375(22):2121-2132